JP4605801B2 - 肥満治療用のｍｃｈアンタゴニスト - Google Patents

肥満治療用のｍｃｈアンタゴニスト Download PDF

Info

Publication number
JP4605801B2
JP4605801B2 JP2006517746A JP2006517746A JP4605801B2 JP 4605801 B2 JP4605801 B2 JP 4605801B2 JP 2006517746 A JP2006517746 A JP 2006517746A JP 2006517746 A JP2006517746 A JP 2006517746A JP 4605801 B2 JP4605801 B2 JP 4605801B2
Authority
JP
Japan
Prior art keywords
compound
group
alkyl
aryl
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006517746A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007521286A5 (enExample
JP2007521286A (ja
Inventor
アナンダン パラニ，
シェリー エー． シャーピロ，
フーベルト ビー． ジョシェン，
トーマス エー． バラ，
ジョン ダブリュー． クレーダー，
パラディープ ビー． パシュパバナム，
シェンジャン リー，
マーク マクブライアー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of JP2007521286A publication Critical patent/JP2007521286A/ja
Publication of JP2007521286A5 publication Critical patent/JP2007521286A5/ja
Application granted granted Critical
Publication of JP4605801B2 publication Critical patent/JP4605801B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2006517746A 2003-06-30 2004-06-28 肥満治療用のｍｃｈアンタゴニスト Expired - Fee Related JP4605801B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48361903P 2003-06-30 2003-06-30
PCT/US2004/020763 WO2005005419A1 (en) 2003-06-30 2004-06-28 Mch antagonists for the treatment of obesity

Publications (3)

Publication Number Publication Date
JP2007521286A JP2007521286A (ja) 2007-08-02
JP2007521286A5 JP2007521286A5 (enExample) 2008-02-28
JP4605801B2 true JP4605801B2 (ja) 2011-01-05

Family

ID=34061963

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006517746A Expired - Fee Related JP4605801B2 (ja) 2003-06-30 2004-06-28 肥満治療用のｍｃｈアンタゴニスト

Country Status (7)

Country Link
US (1) US7345042B2 (enExample)
EP (1) EP1644366A1 (enExample)
JP (1) JP4605801B2 (enExample)
CN (1) CN1812985A (enExample)
CA (1) CA2526725A1 (enExample)
MX (1) MXPA05013596A (enExample)
WO (1) WO2005005419A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2562235C (en) 2004-04-13 2013-09-24 Incyte Corporation Piperazinylpiperidine derivatives as chemokine receptor antagonists
US20080027072A1 (en) * 2006-04-20 2008-01-31 Ampla Pharmaceuticals, Inc. Potentiation of MC4 receptor activity
US20080108586A1 (en) * 2006-09-06 2008-05-08 Incyte Corporation Combination therapy for human immunodeficiency virus infection
CN117100751A (zh) 2017-06-20 2023-11-24 安布里亚制药公司 用于提高心脏代谢效率的组合物和方法
EP3866794B1 (en) 2018-10-17 2024-12-04 Imbria Pharmaceuticals, Inc. Methods of treating rheumatic diseases using trimetazidine-based compounds
US11530184B2 (en) 2020-06-30 2022-12-20 Imbria Pharmaceuticals, Inc. Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11780811B2 (en) 2020-06-30 2023-10-10 Imbria Pharmaceuticals, Inc. Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11883396B2 (en) 2021-05-03 2024-01-30 Imbria Pharmaceuticals, Inc. Methods of treating kidney conditions using modified forms of trimetazidine

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117149A0 (en) 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
US5889006A (en) 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
US5908830A (en) 1996-10-31 1999-06-01 Merck & Co., Inc. Combination therapy for the treatment of diabetes and obesity
US6391865B1 (en) * 1999-05-04 2002-05-21 Schering Corporation Piperazine derivatives useful as CCR5 antagonists
DE60021370C5 (de) 1999-05-04 2007-11-08 Schering Corp. Piperazinderivate verwendbar als ccr5 antagonisten
CA2414198A1 (en) * 2000-07-06 2002-01-17 Neurogen Corporation Melanin concentrating hormone receptor ligands
US6900329B2 (en) * 2001-03-21 2005-05-31 Schering Corporation MCH antagonists and their use in the treatment of obesity
EP1389189A2 (en) * 2001-05-22 2004-02-18 Neurogen Corporation Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues
WO2003045918A1 (en) * 2001-11-26 2003-06-05 Schering Corporation Piperidine-based mch antagonists for treatment of obesity and cns disorders
EP1465888A2 (en) * 2002-01-10 2004-10-13 Neurogen Corporation Melanin concentrating hormone receptor ligands: substituted benzoimidazole analogues
WO2004078717A1 (en) * 2003-03-03 2004-09-16 Merck & Co., Inc. Acylated piperazine derivatives as melanocortin-4 receptor agonists
CA2529161A1 (en) * 2003-06-13 2004-12-29 Schering Aktiengesellschaft Quinolyl amide derivatives as ccr-5 antagonists

Also Published As

Publication number Publication date
WO2005005419A1 (en) 2005-01-20
CA2526725A1 (en) 2005-01-20
US20050004121A1 (en) 2005-01-06
CN1812985A (zh) 2006-08-02
MXPA05013596A (es) 2006-03-09
EP1644366A1 (en) 2006-04-12
JP2007521286A (ja) 2007-08-02
US7345042B2 (en) 2008-03-18

Similar Documents

Publication Publication Date Title
JP4335532B2 (ja) Ｍｃｈアンタゴニストおよび肥満治療でのそれらの使用
JP4643141B2 (ja) 肥満治療用のｍｃｈアンタゴニスト
JP2005510563A (ja) 肥満およびｃｎｓ障害の処置のためのピペリジン系ｍｃｈアンタゴニスト
JP2010047618A (ja) 肥満症および関連障害の処置のための、選択的メラニン凝集ホルモンレセプターアンタゴニストとしての２置換ベンズイミダゾール誘導体。
JP4330996B2 (ja) 肥満の処置のためのｍｃｈアンタゴニストとしてのｎ−アリール−ｎ’−アリールシクロアルキル−尿素−誘導体
JP2009102430A (ja) Ｍｃｈアンタゴニストとして使用されるアリールピペリジンおよびビアリールピペリジン
JP2011006469A (ja) 肥満および関連障害の処置のための選択的メラニン濃縮ホルモンレセプターアンタゴニストとしての二環式化合物
JP4522853B2 (ja) 肥満の処置のための選択的メラニン濃縮ホルモンレセプターアンタゴニストとしてのスピロ置換ピペリジン
JP4605801B2 (ja) 肥満治療用のｍｃｈアンタゴニスト
JP2007521286A5 (enExample)
JP4570165B2 (ja) 肥満および関連障害の処置のための選択的ｍｃｈレセプターアンタゴニストとしてのビアリールテトラヒドロイソキノリンピペリジン
JP4672662B2 (ja) 肥満およびそれに関連した障害を治療するための選択的メラニン濃縮ホルモンレセプタアンタゴニストとしての２−置換ベンゾイミダゾールピペリジン
JP2006520399A5 (enExample)
JP2007504146A5 (enExample)
EP1667679B1 (en) Aminobenzimidazoles as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders
CN101014589A (zh) 作为选择性黑色素聚集激素拮抗剂的新型杂环和其用于治疗肥胖症及相关疾病

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070525

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070525

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20080108

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100702

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20100707

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100831

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100929

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20101004

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131015

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees